Immunome, Inc. Contract Liability (Deferred Revenue)
Immunome, Inc. (IMNM) had Contract Liability (Deferred Revenue) of $0 as of 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-03-03
- 2025-12-31: Contract with Customer, Liability, Current $0.00.
- 2025-09-30: Contract with Customer, Liability, Current $0.00.
- 2025-06-30: Contract with Customer, Liability, Current $0.00.
- 2025-03-31: Contract with Customer, Liability, Current $4.01M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-03 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-06 |
| 2025-03-31 | $4.01M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $6.94M 10-K · filed 2026-03-03 |
| 2024-09-30 | $9.68M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $12.59M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $12.74M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $10.49M 10-K · filed 2025-03-19 |
| 2023-09-30 | $16.96M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $17.67M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $18.21M 10-Q · filed 2023-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |